Review



polyplex nps  (Malvern Panalytical)


Bioz Verified Symbol Malvern Panalytical is a verified supplier
Bioz Manufacturer Symbol Malvern Panalytical manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Malvern Panalytical polyplex nps
    A) When incubated in blood at 37°C, a significant fraction of the PEGylated polyplexes remained in the serum, indicating that they nonspecifically interact with erythrocytes to a significantly lesser degree than PEI (p<0.05). B) FRET-NP incubation in diluted human whole blood suggested that all PEGylated <t>polyplex</t> NPs were significantly more serum stable than the commercial standard Lipofectamine 2000 (p<0.05). Statistical significance for A-B was evaluated by ANOVA at a confidence level of p<0.05 where all groups were found to be significant except for those designated with †. C) Stability of FRET-NPs incubated in 2 U/mL of heparin was enhanced for polyplexes with 40-60% BMA content in the core-forming polymer block. D) The circulation half-life was 18.4 min for 50B and 5.8 min for 0B (p<0.05, n=3). E) When measured intravitally, systemic biodistribution was significantly higher (p<0.05) for the 50B injected mice. F) Intravital imaging of intravenously injected 50B and 0B polyplex NPs reveals rapid kidney distribution and systemic clearance of 0B. G) Representative time course images are shown noting significantly more overall systemic biodistribution of fluorescent siRNA delivered via 50B polyplexes relative to the more rapidly cleared 0B polyplexes. H) Imaging of siRNA fluorescence in kidneys excised at 5 minutes post injection confirmed increased, rapid renal filtration of siRNA delivered via 0B polyplex NPs relative to the 50B group. I) Postmortem tissue biodistribution showed preferential accumulation in liver and kidneys, with significantly decreased systemic clearance of 50B vs 0B at 20 min, 1 hr, and 2 hrs post-injection (p<0.05, n=3). J) Measurement of cumulative fluorescence in all of the organs at 2hr post injection showed significantly increased biodistribution and retention in the organs for 50B relative to 0B polyplex NPs (p<0.05). K) Representative tissue biodistribution images are shown from 2h. Statistical significance for in vivo experiments was evaluated with ANOVA at a confidence level of p<0.05, and * designates significance.
    Polyplex Nps, supplied by Malvern Panalytical, used in various techniques. Bioz Stars score: 99/100, based on 207649 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyplex nps/product/Malvern Panalytical
    Average 99 stars, based on 207649 article reviews
    polyplex nps - by Bioz Stars, 2026-06
    99/100 stars

    Images

    1) Product Images from "Balancing Cationic and Hydrophobic Content of PEGylated siRNA Polyplexes Enhances Endosome Escape, Stability, Blood Circulation Time, and Bioactivity In Vivo"

    Article Title: Balancing Cationic and Hydrophobic Content of PEGylated siRNA Polyplexes Enhances Endosome Escape, Stability, Blood Circulation Time, and Bioactivity In Vivo

    Journal: ACS nano

    doi: 10.1021/nn403325f

    A) When incubated in blood at 37°C, a significant fraction of the PEGylated polyplexes remained in the serum, indicating that they nonspecifically interact with erythrocytes to a significantly lesser degree than PEI (p<0.05). B) FRET-NP incubation in diluted human whole blood suggested that all PEGylated polyplex NPs were significantly more serum stable than the commercial standard Lipofectamine 2000 (p<0.05). Statistical significance for A-B was evaluated by ANOVA at a confidence level of p<0.05 where all groups were found to be significant except for those designated with †. C) Stability of FRET-NPs incubated in 2 U/mL of heparin was enhanced for polyplexes with 40-60% BMA content in the core-forming polymer block. D) The circulation half-life was 18.4 min for 50B and 5.8 min for 0B (p<0.05, n=3). E) When measured intravitally, systemic biodistribution was significantly higher (p<0.05) for the 50B injected mice. F) Intravital imaging of intravenously injected 50B and 0B polyplex NPs reveals rapid kidney distribution and systemic clearance of 0B. G) Representative time course images are shown noting significantly more overall systemic biodistribution of fluorescent siRNA delivered via 50B polyplexes relative to the more rapidly cleared 0B polyplexes. H) Imaging of siRNA fluorescence in kidneys excised at 5 minutes post injection confirmed increased, rapid renal filtration of siRNA delivered via 0B polyplex NPs relative to the 50B group. I) Postmortem tissue biodistribution showed preferential accumulation in liver and kidneys, with significantly decreased systemic clearance of 50B vs 0B at 20 min, 1 hr, and 2 hrs post-injection (p<0.05, n=3). J) Measurement of cumulative fluorescence in all of the organs at 2hr post injection showed significantly increased biodistribution and retention in the organs for 50B relative to 0B polyplex NPs (p<0.05). K) Representative tissue biodistribution images are shown from 2h. Statistical significance for in vivo experiments was evaluated with ANOVA at a confidence level of p<0.05, and * designates significance.
    Figure Legend Snippet: A) When incubated in blood at 37°C, a significant fraction of the PEGylated polyplexes remained in the serum, indicating that they nonspecifically interact with erythrocytes to a significantly lesser degree than PEI (p<0.05). B) FRET-NP incubation in diluted human whole blood suggested that all PEGylated polyplex NPs were significantly more serum stable than the commercial standard Lipofectamine 2000 (p<0.05). Statistical significance for A-B was evaluated by ANOVA at a confidence level of p<0.05 where all groups were found to be significant except for those designated with †. C) Stability of FRET-NPs incubated in 2 U/mL of heparin was enhanced for polyplexes with 40-60% BMA content in the core-forming polymer block. D) The circulation half-life was 18.4 min for 50B and 5.8 min for 0B (p<0.05, n=3). E) When measured intravitally, systemic biodistribution was significantly higher (p<0.05) for the 50B injected mice. F) Intravital imaging of intravenously injected 50B and 0B polyplex NPs reveals rapid kidney distribution and systemic clearance of 0B. G) Representative time course images are shown noting significantly more overall systemic biodistribution of fluorescent siRNA delivered via 50B polyplexes relative to the more rapidly cleared 0B polyplexes. H) Imaging of siRNA fluorescence in kidneys excised at 5 minutes post injection confirmed increased, rapid renal filtration of siRNA delivered via 0B polyplex NPs relative to the 50B group. I) Postmortem tissue biodistribution showed preferential accumulation in liver and kidneys, with significantly decreased systemic clearance of 50B vs 0B at 20 min, 1 hr, and 2 hrs post-injection (p<0.05, n=3). J) Measurement of cumulative fluorescence in all of the organs at 2hr post injection showed significantly increased biodistribution and retention in the organs for 50B relative to 0B polyplex NPs (p<0.05). K) Representative tissue biodistribution images are shown from 2h. Statistical significance for in vivo experiments was evaluated with ANOVA at a confidence level of p<0.05, and * designates significance.

    Techniques Used: Incubation, Polymer, Blocking Assay, Injection, Imaging, Fluorescence, Filtration, In Vivo



    Similar Products

    polyplex nps  (Malvern Panalytical)
    99
    Malvern Panalytical polyplex nps
    A) When incubated in blood at 37°C, a significant fraction of the PEGylated polyplexes remained in the serum, indicating that they nonspecifically interact with erythrocytes to a significantly lesser degree than PEI (p<0.05). B) FRET-NP incubation in diluted human whole blood suggested that all PEGylated <t>polyplex</t> NPs were significantly more serum stable than the commercial standard Lipofectamine 2000 (p<0.05). Statistical significance for A-B was evaluated by ANOVA at a confidence level of p<0.05 where all groups were found to be significant except for those designated with †. C) Stability of FRET-NPs incubated in 2 U/mL of heparin was enhanced for polyplexes with 40-60% BMA content in the core-forming polymer block. D) The circulation half-life was 18.4 min for 50B and 5.8 min for 0B (p<0.05, n=3). E) When measured intravitally, systemic biodistribution was significantly higher (p<0.05) for the 50B injected mice. F) Intravital imaging of intravenously injected 50B and 0B polyplex NPs reveals rapid kidney distribution and systemic clearance of 0B. G) Representative time course images are shown noting significantly more overall systemic biodistribution of fluorescent siRNA delivered via 50B polyplexes relative to the more rapidly cleared 0B polyplexes. H) Imaging of siRNA fluorescence in kidneys excised at 5 minutes post injection confirmed increased, rapid renal filtration of siRNA delivered via 0B polyplex NPs relative to the 50B group. I) Postmortem tissue biodistribution showed preferential accumulation in liver and kidneys, with significantly decreased systemic clearance of 50B vs 0B at 20 min, 1 hr, and 2 hrs post-injection (p<0.05, n=3). J) Measurement of cumulative fluorescence in all of the organs at 2hr post injection showed significantly increased biodistribution and retention in the organs for 50B relative to 0B polyplex NPs (p<0.05). K) Representative tissue biodistribution images are shown from 2h. Statistical significance for in vivo experiments was evaluated with ANOVA at a confidence level of p<0.05, and * designates significance.
    Polyplex Nps, supplied by Malvern Panalytical, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyplex nps/product/Malvern Panalytical
    Average 99 stars, based on 1 article reviews
    polyplex nps - by Bioz Stars, 2026-06
    99/100 stars
    		  Buy from Supplier
    neurotensin (nts)-polyplex nps  (NanoCarrier Co)
    90
    NanoCarrier Co neurotensin (nts)-polyplex nps
    A) When incubated in blood at 37°C, a significant fraction of the PEGylated polyplexes remained in the serum, indicating that they nonspecifically interact with erythrocytes to a significantly lesser degree than PEI (p<0.05). B) FRET-NP incubation in diluted human whole blood suggested that all PEGylated <t>polyplex</t> NPs were significantly more serum stable than the commercial standard Lipofectamine 2000 (p<0.05). Statistical significance for A-B was evaluated by ANOVA at a confidence level of p<0.05 where all groups were found to be significant except for those designated with †. C) Stability of FRET-NPs incubated in 2 U/mL of heparin was enhanced for polyplexes with 40-60% BMA content in the core-forming polymer block. D) The circulation half-life was 18.4 min for 50B and 5.8 min for 0B (p<0.05, n=3). E) When measured intravitally, systemic biodistribution was significantly higher (p<0.05) for the 50B injected mice. F) Intravital imaging of intravenously injected 50B and 0B polyplex NPs reveals rapid kidney distribution and systemic clearance of 0B. G) Representative time course images are shown noting significantly more overall systemic biodistribution of fluorescent siRNA delivered via 50B polyplexes relative to the more rapidly cleared 0B polyplexes. H) Imaging of siRNA fluorescence in kidneys excised at 5 minutes post injection confirmed increased, rapid renal filtration of siRNA delivered via 0B polyplex NPs relative to the 50B group. I) Postmortem tissue biodistribution showed preferential accumulation in liver and kidneys, with significantly decreased systemic clearance of 50B vs 0B at 20 min, 1 hr, and 2 hrs post-injection (p<0.05, n=3). J) Measurement of cumulative fluorescence in all of the organs at 2hr post injection showed significantly increased biodistribution and retention in the organs for 50B relative to 0B polyplex NPs (p<0.05). K) Representative tissue biodistribution images are shown from 2h. Statistical significance for in vivo experiments was evaluated with ANOVA at a confidence level of p<0.05, and * designates significance.
    Neurotensin (Nts) Polyplex Nps, supplied by NanoCarrier Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/neurotensin (nts)-polyplex nps/product/NanoCarrier Co
    Average 90 stars, based on 1 article reviews
    neurotensin (nts)-polyplex nps - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    nts-polyplex nps  (NanoCarrier Co)
    90
    NanoCarrier Co nts-polyplex nps
    A) When incubated in blood at 37°C, a significant fraction of the PEGylated polyplexes remained in the serum, indicating that they nonspecifically interact with erythrocytes to a significantly lesser degree than PEI (p<0.05). B) FRET-NP incubation in diluted human whole blood suggested that all PEGylated <t>polyplex</t> NPs were significantly more serum stable than the commercial standard Lipofectamine 2000 (p<0.05). Statistical significance for A-B was evaluated by ANOVA at a confidence level of p<0.05 where all groups were found to be significant except for those designated with †. C) Stability of FRET-NPs incubated in 2 U/mL of heparin was enhanced for polyplexes with 40-60% BMA content in the core-forming polymer block. D) The circulation half-life was 18.4 min for 50B and 5.8 min for 0B (p<0.05, n=3). E) When measured intravitally, systemic biodistribution was significantly higher (p<0.05) for the 50B injected mice. F) Intravital imaging of intravenously injected 50B and 0B polyplex NPs reveals rapid kidney distribution and systemic clearance of 0B. G) Representative time course images are shown noting significantly more overall systemic biodistribution of fluorescent siRNA delivered via 50B polyplexes relative to the more rapidly cleared 0B polyplexes. H) Imaging of siRNA fluorescence in kidneys excised at 5 minutes post injection confirmed increased, rapid renal filtration of siRNA delivered via 0B polyplex NPs relative to the 50B group. I) Postmortem tissue biodistribution showed preferential accumulation in liver and kidneys, with significantly decreased systemic clearance of 50B vs 0B at 20 min, 1 hr, and 2 hrs post-injection (p<0.05, n=3). J) Measurement of cumulative fluorescence in all of the organs at 2hr post injection showed significantly increased biodistribution and retention in the organs for 50B relative to 0B polyplex NPs (p<0.05). K) Representative tissue biodistribution images are shown from 2h. Statistical significance for in vivo experiments was evaluated with ANOVA at a confidence level of p<0.05, and * designates significance.
    Nts Polyplex Nps, supplied by NanoCarrier Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nts-polyplex nps/product/NanoCarrier Co
    Average 90 stars, based on 1 article reviews
    nts-polyplex nps - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    A) When incubated in blood at 37°C, a significant fraction of the PEGylated polyplexes remained in the serum, indicating that they nonspecifically interact with erythrocytes to a significantly lesser degree than PEI (p<0.05). B) FRET-NP incubation in diluted human whole blood suggested that all PEGylated polyplex NPs were significantly more serum stable than the commercial standard Lipofectamine 2000 (p<0.05). Statistical significance for A-B was evaluated by ANOVA at a confidence level of p<0.05 where all groups were found to be significant except for those designated with †. C) Stability of FRET-NPs incubated in 2 U/mL of heparin was enhanced for polyplexes with 40-60% BMA content in the core-forming polymer block. D) The circulation half-life was 18.4 min for 50B and 5.8 min for 0B (p<0.05, n=3). E) When measured intravitally, systemic biodistribution was significantly higher (p<0.05) for the 50B injected mice. F) Intravital imaging of intravenously injected 50B and 0B polyplex NPs reveals rapid kidney distribution and systemic clearance of 0B. G) Representative time course images are shown noting significantly more overall systemic biodistribution of fluorescent siRNA delivered via 50B polyplexes relative to the more rapidly cleared 0B polyplexes. H) Imaging of siRNA fluorescence in kidneys excised at 5 minutes post injection confirmed increased, rapid renal filtration of siRNA delivered via 0B polyplex NPs relative to the 50B group. I) Postmortem tissue biodistribution showed preferential accumulation in liver and kidneys, with significantly decreased systemic clearance of 50B vs 0B at 20 min, 1 hr, and 2 hrs post-injection (p<0.05, n=3). J) Measurement of cumulative fluorescence in all of the organs at 2hr post injection showed significantly increased biodistribution and retention in the organs for 50B relative to 0B polyplex NPs (p<0.05). K) Representative tissue biodistribution images are shown from 2h. Statistical significance for in vivo experiments was evaluated with ANOVA at a confidence level of p<0.05, and * designates significance.

    Journal: ACS nano

    Article Title: Balancing Cationic and Hydrophobic Content of PEGylated siRNA Polyplexes Enhances Endosome Escape, Stability, Blood Circulation Time, and Bioactivity In Vivo

    doi: 10.1021/nn403325f

    Figure Lengend Snippet: A) When incubated in blood at 37°C, a significant fraction of the PEGylated polyplexes remained in the serum, indicating that they nonspecifically interact with erythrocytes to a significantly lesser degree than PEI (p<0.05). B) FRET-NP incubation in diluted human whole blood suggested that all PEGylated polyplex NPs were significantly more serum stable than the commercial standard Lipofectamine 2000 (p<0.05). Statistical significance for A-B was evaluated by ANOVA at a confidence level of p<0.05 where all groups were found to be significant except for those designated with †. C) Stability of FRET-NPs incubated in 2 U/mL of heparin was enhanced for polyplexes with 40-60% BMA content in the core-forming polymer block. D) The circulation half-life was 18.4 min for 50B and 5.8 min for 0B (p<0.05, n=3). E) When measured intravitally, systemic biodistribution was significantly higher (p<0.05) for the 50B injected mice. F) Intravital imaging of intravenously injected 50B and 0B polyplex NPs reveals rapid kidney distribution and systemic clearance of 0B. G) Representative time course images are shown noting significantly more overall systemic biodistribution of fluorescent siRNA delivered via 50B polyplexes relative to the more rapidly cleared 0B polyplexes. H) Imaging of siRNA fluorescence in kidneys excised at 5 minutes post injection confirmed increased, rapid renal filtration of siRNA delivered via 0B polyplex NPs relative to the 50B group. I) Postmortem tissue biodistribution showed preferential accumulation in liver and kidneys, with significantly decreased systemic clearance of 50B vs 0B at 20 min, 1 hr, and 2 hrs post-injection (p<0.05, n=3). J) Measurement of cumulative fluorescence in all of the organs at 2hr post injection showed significantly increased biodistribution and retention in the organs for 50B relative to 0B polyplex NPs (p<0.05). K) Representative tissue biodistribution images are shown from 2h. Statistical significance for in vivo experiments was evaluated with ANOVA at a confidence level of p<0.05, and * designates significance.

    Article Snippet: Hydrodynamic diameter and zeta potential of the resulting polyplex NPs were measured using a Malvern Zetasizer Nano ZS.

    Techniques: Incubation, Polymer, Blocking Assay, Injection, Imaging, Fluorescence, Filtration, In Vivo